Last updated on May 2019

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL


Brief description of study

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Detailed Study Description

This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, patients will be enrolled using an accelerated titration design. The starting dose of LOXO-305 in oral tablet form is 25 mg/day (e.g., 25 mg once daily [QD]). Once the MTD and/or RP2D is identified, patients will be enrolled to one of six phase 2 dose expansion cohorts depending on tumor histology, tumor genotype, and prior treatment history. Cycle length will be 28 days.

Clinical Study Identifier: NCT03740529

Find a site near you

Start Over

Florida Cancer Specialists

Sarasota, FL United States
5.29miles
  Connect »